Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of “Buy” by Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have received a consensus recommendation of “Buy” from the eleven ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $47.5714.

IMUX has been the subject of a number of analyst reports. Lifesci Capital upgraded Immunic to a “strong-buy” rating in a research report on Monday, May 4th. Roth Capital restated a “buy” rating and set a $19.00 price objective on shares of Immunic in a research note on Thursday, May 14th. D. Boral Capital downgraded shares of Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, April 15th. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price (up from $5.00) on shares of Immunic in a research report on Thursday, April 30th. Finally, Stifel Nicolaus set a $25.00 price target on shares of Immunic and gave the stock a “buy” rating in a research report on Thursday, April 16th.

Immunic Stock Up 3.4%

Shares of NASDAQ:IMUX opened at $15.36 on Wednesday. The company’s 50-day moving average price is $13.25 and its 200 day moving average price is $10.43. The company has a market cap of $209.20 million, a PE ratio of -2.75 and a beta of 1.37. Immunic has a fifty-two week low of $5.06 and a fifty-two week high of $15.84.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.37). As a group, equities analysts anticipate that Immunic will post -4.57 EPS for the current year.

Hedge Funds Weigh In On Immunic

Several hedge funds have recently modified their holdings of IMUX. CTC Alternative Strategies Ltd. acquired a new stake in shares of Immunic in the first quarter valued at $27,000. Qube Research & Technologies Ltd bought a new stake in Immunic in the third quarter worth about $29,000. ADAR1 Capital Management LLC bought a new stake in Immunic in the first quarter worth about $33,000. Two Sigma Investments LP acquired a new stake in Immunic in the 3rd quarter valued at about $52,000. Finally, Seven Fleet Capital Management LP acquired a new stake in Immunic in the 4th quarter valued at about $83,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.